BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56. [PMID: 22921639 DOI: 10.1053/j.ajkd.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Stivelman JC. Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn). Semin Dial 2017;30:142-8. [PMID: 28083917 DOI: 10.1111/sdi.12569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Hasegawa T, Zhao J, Fuller DS, Bieber B, Zee J, Morgenstern H, Hanafusa N, Nangaku M. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins. Am J Nephrol 2017;46:11-7. [PMID: 28564644 DOI: 10.1159/000477217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
3 Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP; Collaborative Study Group. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res 2015;15:545-50. [PMID: 25495878 DOI: 10.1586/14737167.2015.995169] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
4 Ravera M, Bussalino E, Paoletti E, Bellasi A, Di Lullo L, Fusaro M. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator? International Journal of Cardiology 2019;274:179-85. [DOI: 10.1016/j.ijcard.2018.07.066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
5 Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014;29:1493-505. [PMID: 24005791 DOI: 10.1007/s00467-013-2557-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pramod S, Goldfarb DS. Challenging patient phenotypes in the management of anaemia of chronic kidney disease. Int J Clin Pract 2021;:e14681. [PMID: 34331826 DOI: 10.1111/ijcp.14681] [Reference Citation Analysis]
7 Raichoudhury R, Spinowitz BS. Treatment of anemia in difficult-to-manage patients with chronic kidney disease. Kidney Int Suppl (2011) 2021;11:26-34. [PMID: 33777493 DOI: 10.1016/j.kisu.2020.12.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fishbane S. Anemia management: a historical perspective. Kidney International Supplements 2021;11:3-7. [DOI: 10.1016/j.kisu.2020.12.004] [Reference Citation Analysis]
9 Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, Kim SG, Lim SK, Vareesangthip K, Hung CC, Nangaku M; APSN HIF-PHI Recommendation Committee. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carlton) 2021;26:105-18. [PMID: 33222343 DOI: 10.1111/nep.13835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Lee EW, Wallace BC, Galaviz KI, Ho JC. MMiDaS-AE: Multi-modal Missing Data aware Stacked Autoencoder for Biomedical Abstract Screening. Proc ACM Conf Health Inference Learn (2020) 2020;2020:139-50. [PMID: 34308444 DOI: 10.1145/3368555.3384463] [Reference Citation Analysis]
11 Agüera ML, Martin-Malo A, Alvarez-Lara MA, Garcia-Montemayor VE, Canton P, Soriano S, Aljama P. Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis. PLoS One 2015;10:e0135967. [PMID: 26322790 DOI: 10.1371/journal.pone.0135967] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
12 Patel H, Joharapurkar AA, Pandya VB, Patel VJ, Kshirsagar SG, Patel P, Gevriya B, Jain MR, Srinivas NR, Patel PR, Desai RC. Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. Xenobiotica 2018;48:37-44. [DOI: 10.1080/00498254.2016.1278287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Huang WH, Hsu CW, Weng CH, Lin-Tan DT, Yen TH. Negative Relationship between Erythropoietin Dose and Blood Lead Level in Patients Undergoing Maintenance Hemodialysis. Sci Rep 2016;6:34313. [PMID: 27680289 DOI: 10.1038/srep34313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Pérez-García R, Varas J, Cives A, Martín-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI; ORD group. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant 2018;33:690-9. [PMID: 29036505 DOI: 10.1093/ndt/gfx269] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
15 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, Stevens V, Macdougall IC. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. Nephrology (Carlton) 2017;22:969-76. [PMID: 27699922 DOI: 10.1111/nep.12940] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
17 Minutolo R, Borzumati M, Sposini S, Abaterusso C, Carraro G, Santoboni A, Mura C, Filiberti O, Santoro D, Musacchio R, Imperiali P, Fiorini F, De Nicola L, Russo D. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients. Am J Kidney Dis 2016;68:170-2. [PMID: 26879099 DOI: 10.1053/j.ajkd.2016.01.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
18 Locatelli F, Del Vecchio L. Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease? Nephrology Dialysis Transplantation 2020;35:926-32. [DOI: 10.1093/ndt/gfz031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Kaplan JM, Sharma N, Dikdan S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. Int J Mol Sci 2018;19:E389. [PMID: 29382128 DOI: 10.3390/ijms19020389] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
20 Bonomini M, Piscitani L, Di Liberato L, Sirolli V. Biocompatibility of Surface-Modified Membranes for Chronic Hemodialysis Therapy. Biomedicines 2022;10:844. [DOI: 10.3390/biomedicines10040844] [Reference Citation Analysis]
21 Samavat S, Nafar M, Khoshdel A, Alipour- Abedi B. Factors Contributing to Erythropoietin Hyporesponsiveness Among Hemodialysis Patients: A Cross-Sectional Multicenter Study. Nephrourol Mon 2017;In Press. [DOI: 10.5812/numonthly.45003] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Fu Z, Geng X, Chi K, Song C, Wu D, Liu C, Hong Q. Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis. Front Pharmacol 2022;13:746265. [DOI: 10.3389/fphar.2022.746265] [Reference Citation Analysis]
23 Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi JM, Heine GH, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verhaar MC, Wiecek A, Wuerzner G, London GM, Zoccali C. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant 2017;32:620-40. [PMID: 28340239 DOI: 10.1093/ndt/gfw433] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
24 Lee SW, Kim JM, Lim HJ, Hwang YH, Kim SW, Chung W, Oh KH, Ahn C, Lee KB, Sung SA. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Sci Rep 2017;7:4260. [PMID: 28652624 DOI: 10.1038/s41598-017-04664-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
25 Li L, Li C, Zhou Y, Xu Q, Wang Z, Zhu X, Ba Y. Effects of Jianpi Bushen Therapy for Treatment of CKD Anemia: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2020;11:560920. [PMID: 33041799 DOI: 10.3389/fphar.2020.560920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Du XL, Zhang Y, Hardy D. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer. Cancer Causes Control 2016;27:695-707. [PMID: 27059219 DOI: 10.1007/s10552-016-0742-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Liu C, Fu Z, Jiang J, Chi K, Geng X, Mao Z, Song C, Sun G, Hong Q, Cai G, Chen X, Sun X. Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis. Front Med (Lausanne) 2021;8:724456. [PMID: 34532333 DOI: 10.3389/fmed.2021.724456] [Reference Citation Analysis]
28 Borawski B, Malyszko JS, Kwiatkowska M, Malyszko J. Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today. J Clin Med 2021;10:4149. [PMID: 34575261 DOI: 10.3390/jcm10184149] [Reference Citation Analysis]
29 Latcha S. Anemia management in cancer patients with chronic kidney disease. Semin Dial 2019;32:513-9. [PMID: 31596520 DOI: 10.1111/sdi.12841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kokado Y, Kawai K, Nanjo T, Kinoshita S, Kondo K. In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor. Clin Ther 2021;43:1408-1418.e5. [PMID: 34511184 DOI: 10.1016/j.clinthera.2021.06.013] [Reference Citation Analysis]
31 Xu L, Chen Y, Xie Z, He Q, Chen S, Wang W, Liu G, Liao Y, Lu C, Hao L, Sun J, Shi W, Liang X; China collaborative study on AKI (CCS-AKI). High hemoglobin is associated with increased in-hospital death in patients with chronic obstructive pulmonary disease and chronic kidney disease: a retrospective multicenter population-based study. BMC Pulm Med 2019;19:174. [PMID: 31533673 DOI: 10.1186/s12890-019-0933-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ahmadmehrabi S, Tang WHW. Hemodialysis-induced cardiovascular disease. Semin Dial 2018;31:258-67. [PMID: 29624739 DOI: 10.1111/sdi.12694] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
33 Fusco G, Hariri A, Vallarino C, Singh A, Yu P, Wise L. A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease. Ther Adv Drug Saf 2017;8:305-18. [PMID: 29593859 DOI: 10.1177/2042098617716819] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Boyle SM, Berns JS. Erythropoietin and Resistant Hypertension in CKD. Seminars in Nephrology 2014;34:540-9. [DOI: 10.1016/j.semnephrol.2014.08.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
35 Ueda E, Fujikawa T, Toya Y, Kuji T, Kakimoto-Shino M, Kawai Y, Kawano T, Azushima K, Wakui H, Tamura K. Clinical significance of a novel reticulocyte-based erythropoietin resistance index in HD patients: A retrospective study. Ther Apher Dial 2021. [PMID: 34863017 DOI: 10.1111/1744-9987.13772] [Reference Citation Analysis]
36 Clark BA, Osadchuk L, John J, Culver T, Marcus R. Effect of intravenous iron on outcomes of acute kidney injury. Transfusion 2016;56:933-7. [PMID: 26801821 DOI: 10.1111/trf.13471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 Ward F, Holian J, Murray PT. Drug therapies to delay the progression of chronic kidney disease. Clin Med (Lond) 2015;15:550-7. [PMID: 26621944 DOI: 10.7861/clinmedicine.15-6-550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
38 Han J, Ahmadi H, Ladi-Seyedian SS, Clifford TG, Douglawi A, Xu W, Bazargani ST, Mingo S, Thangathurai D, Daneshmand S, Djaladat H. Safety and feasibility of urological procedures in Jehovah's Witness patients. Int J Urol 2021. [PMID: 34642972 DOI: 10.1111/iju.14721] [Reference Citation Analysis]
39 Upadhyay A, Susantitaphong P, Jaber BL. Ultrapure versus standard dialysate: A cost-benefit analysis. Semin Dial 2017;30:398-402. [PMID: 28608933 DOI: 10.1111/sdi.12618] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
40 Chertow GM, Pergola PE, Agarwal R, Block GA, Farag YMK, Jardine AG, Koury MJ, Luo W, Khawaja Z, Lewis EF, Matsushita K, McCullough PA, Parfrey PS, Wittes J, Walters KA, Tseng C, Lin T, Sarnak MJ, Vargo DL, Winkelmayer WC, Eckardt KU. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Am Heart J 2021;235:1-11. [PMID: 33129989 DOI: 10.1016/j.ahj.2020.10.068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Wen Y, Xu Y, Tian H, Jiang S, Jiang G, Li P. Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial. Front Med 2022;9:783387. [DOI: 10.3389/fmed.2022.783387] [Reference Citation Analysis]
42 Nassif ME, Patel JS, Shuster JE, Raymer DS, Jackups R Jr, Novak E, Gage BF, Prasad S, Silvestry SC, Ewald GA, LaRue SJ. Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 2015;3:146-53. [PMID: 25660839 DOI: 10.1016/j.jchf.2014.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
43 Li X, Jiang X, He F, Xia Y, Chen X, Du X, Gan H. Effect of Erythropoietin on Calcification of Vascular Smooth Muscle Cells and Its Molecular Regulatory Mechanism. J Cardiovasc Transl Res 2021;14:525-37. [PMID: 33170442 DOI: 10.1007/s12265-020-10081-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
44 Fravel MA, Bald E, Fraer M. Antihypertensive Agents in the Dialysis Patient. Curr Hypertens Rep 2019;21:5. [PMID: 30659374 DOI: 10.1007/s11906-019-0909-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Ribeiro S, Garrido P, Fernandes J, Vala H, Rocha-Pereira P, Costa E, Belo L, Reis F, Santos-Silva A. Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sci 2016;151:147-56. [PMID: 26924494 DOI: 10.1016/j.lfs.2016.02.088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
46 Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. Am J Nephrol 2017;45:187-99. [PMID: 28118622 DOI: 10.1159/000455166] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 12.4] [Reference Citation Analysis]
47 Arantes LH Jr, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, Scotte F, Wish J. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol 2018;129:79-90. [PMID: 30097240 DOI: 10.1016/j.critrevonc.2018.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
48 Kwon O, Jang HM, Jung HY, Kim YS, Kang SW, Yang CW, Kim NH, Choi JY, Cho JH, Kim CD, Kim YL, Park SH; Clinical Research Center for End-Stage Renal Disease (CRC- ESRD) Investigators. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. PLoS One 2015;10:e0140241. [PMID: 26452232 DOI: 10.1371/journal.pone.0140241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
49 Niikura T, Maruyama Y, Nakashima S, Matsuo N, Tanno Y, Ohkido I, Yokoyama K, Yamamoto H, Yokoo T. Hepcidin/Ferritin Ratios Differ Among Non-Dialyzed Chronic Kidney Disease Patients, and Patients on Hemodialysis and Peritoneal Dialysis. Ther Apher Dial 2019;23:341-6. [PMID: 30411489 DOI: 10.1111/1744-9987.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Kim JY, Steingroever J, Lee KH, Oh J, Choi MJ, Lee J, Larkins NG, Schaefer F, Hong SH, Jeong GH, Shin JI, Kronbichler A. Clinical Interventions and All-Cause Mortality of Patients with Chronic Kidney Disease: An Umbrella Systematic Review of Meta-Analyses. J Clin Med 2020;9:E394. [PMID: 32024136 DOI: 10.3390/jcm9020394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Kular D, Macdougall IC. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Pediatr Nephrol 2019;34:365-78. [PMID: 29569190 DOI: 10.1007/s00467-017-3849-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
52 Piccoli GB, Cabiddu G, Attini R, Parisi S, Fassio F, Loi V, Gerbino M, Biolcati M, Pani A, Todros T. Hypertension in CKD Pregnancy: a Question of Cause and Effect (Cause or Effect? This Is the Question). Curr Hypertens Rep 2016;18:35. [PMID: 27072828 DOI: 10.1007/s11906-016-0644-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
53 Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831-1843. [PMID: 24856028 DOI: 10.1016/s0140-6736(14)60384-6] [Cited by in Crossref: 214] [Cited by in F6Publishing: 106] [Article Influence: 26.8] [Reference Citation Analysis]
54 Felaco P, Felaco M, Franceschelli S, Ferrone A, Gatta DMP, Speranza L, Patruno A, De Lutiis MA, Ballerini P, Sirolli V, Grilli A, Bonomini M, Pesce M. Erythropoietin induces miRNA-210 by JAK2/STAT5 signaling in PBMCs of End-stage Renal Disease patients. FEBS J 2020;287:5167-82. [PMID: 32196922 DOI: 10.1111/febs.15302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Tóth A, Csiki DM, Nagy B, Balogh E, Lente G, Ababneh H, Szöőr Á, Jeney V. Daprodustat Accelerates High Phosphate-Induced Calcification Through the Activation of HIF-1 Signaling. Front Pharmacol 2022;13:798053. [DOI: 10.3389/fphar.2022.798053] [Reference Citation Analysis]
56 Wu T, Qi Y, Ma S, Zhang L, Pu X, Chen K, Zhao Y, Sang S, Xiao J. Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis. Ren Fail 2022;44:529-40. [PMID: 35318873 DOI: 10.1080/0886022X.2022.2050754] [Reference Citation Analysis]
57 Bal Z, Demirci BG, Karakose S, Tutal E, Erkmen Uyar M, Acar NO, Sezer S. Factors Influencing Hemoglobin Variability and Its Association with Mortality in Hemodialysis Patients. ScientificWorldJournal 2018;2018:8065691. [PMID: 29805324 DOI: 10.1155/2018/8065691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
58 Lu X, Zhang J, Wang S, Yu Q, Li H. High Erythropoiesis Resistance Index Is a Significant Predictor of Cardiovascular and All-Cause Mortality in Chinese Maintenance Hemodialysis Patients. Mediators Inflamm 2020;2020:1027230. [PMID: 33293895 DOI: 10.1155/2020/1027230] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey JH. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL. Clin Ther 2016;38:122-135.e6. [PMID: 26730453 DOI: 10.1016/j.clinthera.2015.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
60 Streja E, Park J, Chan TY, Lee J, Soohoo M, Rhee CM, Arah OA, Kalantar-Zadeh K. Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. Int J Nephrol 2016;2016:6087134. [PMID: 27298736 DOI: 10.1155/2016/6087134] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
61 Tummalapalli SL, Chu CD, Tuot DS. Avoiding Overuse of Venipuncture and Laboratory Testing in Hospitalized Patients on Hemodialysis. J Patient Saf 2022;18:e225-6. [PMID: 32569100 DOI: 10.1097/PTS.0000000000000738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Peng L, He Y, Zhang J, Hong D, Li G. Erythropoietin and iron for anemia in HIV-infected patients undergoing maintenance hemodialysis in China: a cross-sectional study. BMC Nephrol 2022;23:60. [PMID: 35135490 DOI: 10.1186/s12882-022-02693-y] [Reference Citation Analysis]
63 Bellinghieri G, Condemi CG, Saitta S, Trifirò G, Gangemi S, Savica V, Buemi M, Santoro D. Erythropoiesis-stimulating agents: dose and mortality risk. J Ren Nutr 2015;25:164-8. [PMID: 25529282 DOI: 10.1053/j.jrn.2014.10.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
64 Berns JS. Moving Away From Hemoglobin-Based Anemia Performance Measures in Dialysis Patients. American Journal of Kidney Diseases 2014;64:486-8. [DOI: 10.1053/j.ajkd.2014.06.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Ahmed SB, Dumanski SM. Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease? Canadian Journal of Cardiology 2019;35:1170-80. [DOI: 10.1016/j.cjca.2019.06.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
66 Galli F, Bonomini M, Bartolini D, Zatini L, Reboldi G, Marcantonini G, Gentile G, Sirolli V, Di Pietro N. Vitamin E (Alpha-Tocopherol) Metabolism and Nutrition in Chronic Kidney Disease. Antioxidants 2022;11:989. [DOI: 10.3390/antiox11050989] [Reference Citation Analysis]
67 De Nicola L, Locatelli F, Conte G, Minutolo R. Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? Drugs 2014;74:159-68. [PMID: 24442793 DOI: 10.1007/s40265-013-0175-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
68 Thadhani R, Guilatco R, Hymes J, Maddux FW, Ahuja A. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. Am J Nephrol 2018;48:214-24. [PMID: 30196301 DOI: 10.1159/000492621] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
69 Aapro M, Gascón P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J. Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. Front Pharmacol 2018;9:1498. [PMID: 30687083 DOI: 10.3389/fphar.2018.01498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
70 Reindl-Schwaighofer R, Oberbauer R. Blood disorders after kidney transplantation. Transplant Rev (Orlando). 2014;28:63-75. [PMID: 24211181 DOI: 10.1016/j.trre.2013.10.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
71 Li X, Liu C, Li Y, Xiong W, Zuo D. Inflammation promotes erythropoietin induced vascular calcification by activating p38 pathway. Bioengineered 2022;13:5277-91. [PMID: 35168476 DOI: 10.1080/21655979.2022.2038430] [Reference Citation Analysis]
72 Masumoto M, Kuragano T, Takata C, Fukui R, Mihara Y, Okamoto R, Iwasaki T, Ookawa S, Aichi M, Yahiro M, Kida A, Nanami M. Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability. Int Urol Nephrol 2021. [PMID: 34390438 DOI: 10.1007/s11255-021-02965-w] [Reference Citation Analysis]
73 Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro C, Halimi JM, Heine G, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verharr MC, Wiecek A, Wuerzner G, London GM, Zoccali C. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). J Hypertens 2017;35:657-76. [PMID: 28157814 DOI: 10.1097/HJH.0000000000001283] [Cited by in Crossref: 30] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
74 Wärme A, Hadimeri U, Hadimeri H, Nasic S, Stegmayr B. High doses of erythropoietin stimulating agents may be a risk factor for AV-fistula stenosis. Clin Hemorheol Microcirc 2019;71:53-7. [PMID: 29914013 DOI: 10.3233/CH-180381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
75 Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. Eur J Pharmacol 2021;912:174583. [PMID: 34678238 DOI: 10.1016/j.ejphar.2021.174583] [Reference Citation Analysis]
76 Collister D, Rigatto C, Tangri N. Anemia management in chronic kidney disease and dialysis: a narrative review. Curr Opin Nephrol Hypertens 2017;26:214-8. [PMID: 28306566 DOI: 10.1097/MNH.0000000000000317] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
77 Yarnoff BO, Hoerger TJ, Simpson SA, Pavkov ME, Burrows NR, Shrestha SS, Williams DE, Zhuo X. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. PLoS One 2016;11:e0157323. [PMID: 27404556 DOI: 10.1371/journal.pone.0157323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 Koike K, Fukami K, Kawaguchi A, Shimamatsu K, Yamagishi S, Okuda S. Regulation of platelet count by erythropoiesis-stimulating agents - iron axis in hemodialysis patients. Int J Nephrol Renovasc Dis 2016;9:73-80. [PMID: 27099526 DOI: 10.2147/IJNRD.S98196] [Reference Citation Analysis]
79 Pan SY, Chiang WC, Chen PM, Liu HH, Chou YH, Lai TS, Lai CF, Chiu YL, Lin WY, Chen YM, Chu TS, Lin SL. Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. Sci Rep 2017;7:44013. [PMID: 28272424 DOI: 10.1038/srep44013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Hu X, Xie J, Chen N. Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia. Kidney Dis (Basel) 2021;7:1-9. [PMID: 33614728 DOI: 10.1159/000510587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Alshamsi I. Extended Literature Review of the role of erythropoietin stimulating agents (ESA) use in the management of post renal transplant anaemia. Transplantation Reports 2022. [DOI: 10.1016/j.tpr.2022.100097] [Reference Citation Analysis]
82 Nangaku M, Kondo K, Ueta K, Kokado Y, Kaneko G, Matsuda H, Kawaguchi Y, Komatsu Y. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transplant 2021;36:1731-41. [PMID: 33650630 DOI: 10.1093/ndt/gfab055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
83 Ishii T, Tanaka T, Nangaku M. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. Ther Clin Risk Manag 2021;17:155-63. [PMID: 33628028 DOI: 10.2147/TCRM.S293879] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Li ZL, Tu Y, Liu BC. Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. Kidney Dis (Basel) 2020;6:65-73. [PMID: 32309288 DOI: 10.1159/000504850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
85 Charlesworth EC, Richardson RM, Battistella M. Cost Savings Using a Protocol Approach to Manage Anemia in a Hemodialysis Unit. Am J Nephrol 2014;39:509-14. [DOI: 10.1159/000363115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
86 Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 2014;29:2021-8. [PMID: 24794833 DOI: 10.1007/s00467-014-2820-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
87 Chaknos CM, Berns JS. Erythropoiesis-Stimulating Agents on Trial: Are Higher Dosages Causing Harm? American Journal of Kidney Diseases 2013;61:6-8. [DOI: 10.1053/j.ajkd.2012.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
88 Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0114-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 20] [Article Influence: 16.2] [Reference Citation Analysis]
89 Mani NS, Ginier E. An Evidence-Based Approach to Conducting Systematic Reviews on CKD. Adv Chronic Kidney Dis 2016;23:355-62. [PMID: 28115078 DOI: 10.1053/j.ackd.2016.11.009] [Reference Citation Analysis]
90 Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, Lhotta K, Weiss G. Iron supplementation and mortality in incident dialysis patients: an observational study. PLoS One 2014;9:e114144. [PMID: 25462819 DOI: 10.1371/journal.pone.0114144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
91 Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf 2016;15:1021-30. [PMID: 27149639 DOI: 10.1080/14740338.2016.1182494] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
92 Kim HJ, Park JI, Yoo KD, Kim Y, Baek H, Kim SH, Chang T, Kim HH, Lee KH, Hwang S, Kim CT, Koo H, Kim JH. Real-world treatment patterns of renal anemia in hemodialysis patients: A multicenter cohort study performed using DialysisNet (RRAHD study). Medicine (Baltimore) 2020;99:e18749. [PMID: 31914095 DOI: 10.1097/MD.0000000000018749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
93 Tanaka S, Kitamura H, Tsuruya K, Kitazono T, Nakano T; FKR Study Collaboration Group. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study. Clin Exp Nephrol 2022. [PMID: 35507237 DOI: 10.1007/s10157-022-02227-8] [Reference Citation Analysis]
94 He J, Zhong X, Zhao L, Gan H. JAK2/STAT3/BMP-2 axis and NF-κB pathway are involved in erythropoietin-induced calcification in rat vascular smooth muscle cells. Clin Exp Nephrol 2019;23:501-12. [PMID: 30406500 DOI: 10.1007/s10157-018-1666-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
95 Groenendaal-van de Meent D, den Adel M, Kerbusch V, van Dijk J, Shibata T, Kato K, Schaddelee M. Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies. Clin Pharmacol Drug Dev 2022. [PMID: 35182045 DOI: 10.1002/cpdd.1076] [Reference Citation Analysis]
96 Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 2014;39:130-41. [PMID: 24513913 DOI: 10.1159/000358336] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
97 Hasegawa T, Koiwa F, Akizawa T. Anemia in conventional hemodialysis: Finding the optimal treatment balance. Semin Dial 2018;31:599-606. [PMID: 29909605 DOI: 10.1111/sdi.12719] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
98 Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301. [PMID: 23438972 DOI: 10.1038/nrneph.2013.21] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
99 Lindenfeld J, Keebler ME. Left ventricular assist device thrombosis: another piece of the puzzle? JACC Heart Fail 2015;3:154-8. [PMID: 25660840 DOI: 10.1016/j.jchf.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
100 Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol 2017;18:14. [PMID: 28077085 DOI: 10.1186/s12882-017-0438-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
101 Singh AK, Fishbane SN. How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?: The Itsy Bitsy Anemia Problem. Semin Dial 2013;26:531-4. [DOI: 10.1111/sdi.12104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 Nangaku M, Kondo K, Takabe S, Ueta K, Tandai T, Kawaguchi Y, Komatsu Y. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents. Ther Apher Dial 2022;26:45-54. [PMID: 34115437 DOI: 10.1111/1744-9987.13699] [Reference Citation Analysis]
103 Eckardt KU, Agarwal R, Farag YM, Jardine AG, Khawaja Z, Koury MJ, Luo W, Matsushita K, McCullough PA, Parfrey P, Ross G, Sarnak MJ, Vargo D, Winkelmayer WC, Chertow GM. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant 2021;36:2039-48. [PMID: 33188693 DOI: 10.1093/ndt/gfaa204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
104 Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One 2014;9:e111838. [PMID: 25392999 DOI: 10.1371/journal.pone.0111838] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 10.8] [Reference Citation Analysis]